Business Dynamics: How Novo Nordisk Lost GLP-1 ...

By Rene Pretorius

June 2, 2025

The GLP-1 drug market, vital for diabetes and obesity treatments, is undergoing a seismic shift—most notably Novo Nordisk GLP-1 market share loss to rising competitors like Eli Lilly. This article unpacks the key
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Urgent Need for Pediatric Heart Devices
Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat
Exploring the MASLD CKD Socioeconomic Link
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
Advancing Heart Transplantation: The Role of the Lumped Parameter Model
Cost Savings and Impact of Comprehensive Medication Management in Healthcare
Hypertension in Young South African Adults
ACS Management Innovations: Transforming Patient Outcomes in Acute Coronary S...
Hypertension Detection: HTN-AI Model for Cardiovascular Risk Stratification
CVD Prevention Models in Sub-Saharan Africa: Insights and Gaps